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acute bronchial asthma, we investigated the effects of platelet-activating factor
(PAF) challenge on systemic oxidant–antioxidant balance in 12 asthmatic patients
(age, 2573[SEM] yr; FEV1, 95710% predicted), using a double blinded, controlled
with Lyso-PAF (L-PAF), cross-over design.
Respiratory system resistance (Rrs), arterial blood gases, peripheral blood
neutrophils and oxidant–antioxidant balance, including thiobarbituric acid (TBA)-
malondialdehyde (MDA) adducts, protein sulphydryls and Trolox equivalent
antioxidant capacity (TEAC), were assessed at baseline and 5, 15 and 45min after
PAF and L-PAF (18 mg each) bronchoprovocation. Urinary leukotriene E4 (uLTE4)
elimination was measured 120min after challenge.
Compared with baseline, as expected, PAF increased significantly Rrs and AaPO2
and decreased PaO2 and peripheral blood neutrophils along with a rebound
neutrophilia and increased uLTE4. By contrast, markers of systemic oxidative stress
remained unaltered throughout the study. Unlike PAF, L-PAF-induced changes were
negligible.
We conclude that there is no systemic oxidant–antioxidant imbalance during
acute bronchoconstriction induced by PAF in these patients with mild asthma.
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.es (R. Rodrı´guez-Roisin).Introduction
In patients with asthma platelet-activating factor
(PAF) inhalation provokes neutropaenia, broncho-
constriction and airway microvascular leakage,ed.
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similar to those observed during naturally occurring
acute asthma.1,2 There is also evidence of in-
creased neutrophil pulmonary sequestration after
PAF and circulating leukocytes in asthmatic pa-
tients show an enhanced oxidative burst.2–4 Ac-
cordingly, it has been suggested that an imbalance
between oxidants and antioxidants may have a role
in the pathogenesis of acute asthma.5 We hypothe-
sised that PAF challenge as a model of acute asthma
would result in an altered systemic oxidant–antiox-
idant balance in the context of an abrupt bronch-
oprovocation resembling airway changes observed
in spontaneous asthma attacks. To this end, we
challenged mild asthmatics with PAF and measured
the markers of oxidative stress in plasma.Methods
Study population
Patients with mild asthma were recruited from our
Outpatient Department for the study, which was
approved by the Ethical Research Committee of the
Hospital Clı´nic. All subjects gave informed written
consent after the purpose, risks and potential
benefits of the study were explained to them. The
inclusion criteria were: no respiratory infection or
exacerbation of asthma within the preceding 6
weeks; FEV1470% predicted and 41.5 L; positive
methacholine (PD20o1.9 mmol) and PAF (X20%
increase of baseline resistance of respiratory
system [Rrs] after PAF [8 mg]) bronchial challenges;
no previous treatment with systemic steroids with-
in the preceding 4 weeks; and, absence of any
systemic or cardiopulmonary disease other than
asthma. Maintenance therapy consisted of rescue
inhaled medication with short-acting b2-adrener-
gics in patients, inhaled glucocorticosteroids in 2,
inhaled long-acting b2-adrenergics in 1, and inhaled
combined therapy in 3. All subjects were non-
smokers and were atopic.
Lung function and peripheral blood cells
The resistance of Rrs, arterial PO2, PCO2 and pH,
the alveolar-arterial PO2 difference (AaPO2), oxy-
gen uptake (V˙O2), CO2 production (V˙CO2), minute
ventilation (V˙E), and total white cell counts in
arterial blood were measured or calculated, as
previously described.1,6 A three-lead electrocardio-
gram, heart rate and systemic pressure and arterial
O2 saturation through a pulseoximeter (HP M1166A,
Hewlett-Packard, Boblingen, Germany) were con-tinuously recorded throughout the whole study.
Measurements of urinary cysteinyl leukotriene E4
(uLTE4), corrected for urinary creatinine and urine
volume, were carried out with a validated enzyme
immunoassay (EIA), as previously described.6,7Markers of oxidative stress
A 10ml arterial blood sample was collected in two
EDTA/citrate tubes, spun immediately at 1000 rpm
for 5min in order to measure plasma antioxidant
capacity. The plasma was aspirated into three clean
eppendorf tubes and stored at 70 1C until ana-
lysed in dry ice. Three samples at each time point
were obtained.
Antioxidant capacity assay: The plasma antiox-
idant capacity TEAC (Trolox equivalent antioxidant
capacity) was measured by the method of Miller et
al.8 TEAC was calculated by defining the concen-
tration, in mmol L1 of TEAC to a 1.0mmol L1
sample of the plasma under investigation.
Lipid peroxides assay: The level of plasma lipid
peroxidation products as thiobarbituric acid (TBA)-
malondialdehyde (MDA) adducts were measured
spectrophotometrically by the method described
by Yagi.9 The final result was expressed as micro-
moles of MDA formed per litre of plasma. In one
patient, this assay was not available.
Protein sulphydryl assay: Protein thiols were
measured using the method of Ellman.10 Oxidized
protein sulphydryls were measured by treating
plasma with 10mM dithiothreitol (DDT), at 4 1C
for 2 h, followed by dialysis overnight at 4 1C
against 2 100 volumes of nitrogen-saturated
PBS. Reduced protein sulphydryls were then mea-
sured with Ellman’s reagent as previously de-
scribed.10Study design
A randomised, double-blinded, L-PAF-controlled,
cross-over design was used. After completing the
first visit for recruitment, patients were challenged
on two separate days 1 week apart with inhaled PAF
(C16) (1-O-Hexadecyl-2-acetyl-sn-glycero-3-phos-
phocholine) (18 mg) or L-PAF (C16) (1-O-Hexadecyl-
sn-glycero-3-phosphocholine) (18 mg) (Novabio-
chem AG, Laufelfingen, Switzerland, each), as
previously described.1,6 All asthma medication
was withheld for 2 days before arrival to the
laboratory. After ensuring steady-state conditions,
a set of duplicate measurements of all variables
were obtained (baseline). Maintenance of steady-
state conditions after PAF/L-PAF challenge was
demonstrated by stability (75%) of both
ARTICLE IN PRESS
PAF, oxidation stress and asthma 521ventilatory and haemodynamic variables, and by
the close agreement between duplicate measure-
ments of mixed expired and arterial O2 and CO2
(within 5%), conditions that were met in all
patients. Duplicate measurements were taken at
5, 15, and 45min following PAF/L-PAF inhalation, as
described previously.1,6 No patient needed rescue
medication with short-acting b2-agonists during the
studies. Samples for uLTE4 measurement were
collected at baseline and 120min after challenge.
Oral fluid intake during the period of study was not
permitted.
Statistical analysis
Results are expressed as mean7SEM and 95%
confidence interval (CI). The effects of PAF/L-PAF
challenge on the different primary end-point
variables were assessed by a two-way analysis of
variance (ANOVA) for repeated measures. When the
latter was significant, post hoc comparisons within
each intervention between each time point and
baseline were performed using paired Student’s t-
test with Bonferroni’s correction. Baseline data for
each variable on each intervention day and uLTE4
levels before and after PAF/L-PAF nebulization
were also analysed using paired Student’s t-test.
Statistical significance was set at Po0:05 or
o0.025 (for Bonferroni’s correction).Results
Baseline data (Before PAF/L-PAF challenge)
Twelve patients (6 females; age, 2573 yr; FEV1,
3.270.4 L [95710% predicted]; FEV1/FVC, 7577%;
and, PD20, 0.570.3 mmol) were enrolled in theTable 1 Baseline findings before Lyso-PAF/PAF challenge
Lyso-PAF
Neutrophils ( 109 L1) 4.570.5
Rrs (cm H2OL
1 s1) 4.270.3
PaO2, (mmHg) 92.171.5
PaCO2 (mmHg) 37.170.9
AaPO2 (mmHg) 10.571.5
ULTE4 (pgmg
1 creatinine) 680.97291.3
TBA-MDA (mmol L1) 1.1670.06
Protein sulfhydryl (mmol L1) 0.4970.02
TEAC (mmol) 1.4170.03
Definition of abbreviations: Rrs: respiratory system resistance
leukotriene E4; TBA-MDA: thiobarbituric acid-malondialdehyde ad
significant.study. Except for small differences in Rrs and
products of lipid peroxidation (Po0:02 each),
without physiological significance, all the other
variables were similar between each study day
(Table 1).
Effects of PAF challenge
All but three patients noticed facial flushing, one
coughed and five became dyspnoeic immediately
after the challenge. Compared to baseline, periph-
eral blood neutrophils fell at 5min (to
3.570.7 109 L1) (Po0:01) followed by a rebound
neutrophilia at 15 and 45min (to 5.170.7 and
5.470.7 109 L1) (Po0:001 each) (Table 2). In
parallel, at 5min Rrs (to 5.570.4 cm H2O L
1 s1)
(Po0:005) and AaPO2 (to 27.172.8mmHg) in-
creased whereas PaO2 decreased (to 76.27
2.1mmHg) (Po0:001 each). By 15 (Po0:001) and
45min (Po0:01), Rrs, AaPO2 and PaO2 were still
abnormal. Heart rate increased (from 7071.7 to
7872.2min1) (Po0:005) at 5min, whereas all the
other ventilatory, haemodynamic and gas exchange
variables, including arterial pH (all within normal
limits at baseline), remained unchanged through-
out the study period. By contrast, no significant
changes were observed in plasma lipid peroxides
measured as TBA-MDA adducts, protein sulphydryls,
nor in plasma antioxidant capacity, measured as
TEAC. PAF challenge increased markedly uLTE4
elimination (to 21447845 pgmg1) (Po0:02) at
120min.
Effects of L-PAF challenge
Except for a small increase in AaPO2 at 5 and
15min, and a mild decrease in PaO2 at 15min
(Po0:01 each), compared to baseline, no other(mean7SEM).
PAF P-values
4.570.6 NS
3.670.3 o0.02
94.572.0 NS
37.371.0 NS
9.072.1 NS
752.17178.9 NS
1.4270.06 o0.02
0.4970.02 NS
1.4270.04 NS
; AaPO2: alveolar-arterial PO2 difference; uLTE4: urinary
ducts; TEAC: Trolox equivalent antioxidant capacity; NS: not
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Table 2 Mean differences (95% CI) from baseline after Lyso-PAF (L-PAF) and PAF challenge.
5min 15min 45min P-value
Neutrophils
( 109 L1)
L-PAF 0.4 (0.3/1.2) 0.6 (0.3/1.5) 0.6 (0.3/1.6) o0.005
PAF 1.1* (1.7/2.7) 0.5* (0.2/0.7) 0.9* (0.5/1.3)
Rrs (cm
H2O L
1 s1)
L-PAF 0.2 (0.2/0.5) 0.3 (0.0/0.6) 0.1 (0.4/0.2) o0.02
PAF 1.9* (1.3/2.6) 1.5* (1.1/2.0) 0.6* (0.1/1.0)
PaO2 (mmHg) L-PAF 3.1 (6.4/0.3) 6.0* (9.8/2.3) 1.6 (4.4/1.3) o0.005
PAF 18.3* (22.6/13.9) 14.3* (18.3/10.4) 5.8* (8.7/2.8)
AaPO2 (mmHg) L-PAF 4.2
* (0.9/7.4) 6.9* (2.8/10.9) 0.2 (1.7/2.0) o0.005
PAF 18.1* (13.1/23.1) 14.3* (10.2/18.4) 4.9* (2.3/7.4)
TBA-MDA
(mmol L1)
L-PAF 0.08 (0.09/0.25) 0.04 (0.38/0.30) 0.01 (0.23/0.22) NS
PAF 0.20 (0.40/0.00) 0.30 (0.50/0.10) 0.20 (0.40/0.10)
Protein
sulfhydryl
(mmol L1)
L-PAF 0.02 (0.04/0.00) 0.01 (0.05/0.02) 0.01 (0.01/0.02) NS
PAF 0.01 (0.03/0.05) 0.01 (0.03/0.05) 0.02 (0.03/0.06)
TEAC (mmol) L-PAF 0.10 (0.19/0.01) 0.05 (0.12/0.03) 0.07 (0.19/0.05) NS
PAF 0.03 (0.13/0.08) 0.06 (0.12/0.01) 0.02 (0.10/0.05)
For definition of abbreviations, see Table 1. All but TBA-MDA adducts (n, 11) variables correspond to 12 patients.
*Significantly different from baseline (for individual P-values, see Results).
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stress and uLTE4 changes were observed after L-
PAF exposure.Discussion
Asthma is a chronic inflammatory disease of the
respiratory tract of unknown aetiology. Recent
evidence indicates that inflammatory abnormalities
exist even in the airways of subjects with mild
disease. In the current study we showed no
increase in systemic markers of oxidative stress in
response to PAF challenge in mild asthmatics. This
was reflected by no change in total antioxidant
capacity and levels of lipid peroxides in plasma
after the challenge in asthmatics. In this regard,
Rahman and colleagues3 reported similar levels of
lipid peroxides and proteins sulphydryls in the
plasma of healthy nonsmokers and stable asthmatic
patients to those observed in our study. However,
these markers of systemic oxidative stress in-
creased in spontaneous acute severe asthma. Thus,
PAF inhalation as a model of acute asthma in our
study did not produce increased systemic oxidative
stress despite inducing consistent lung functiondisturbances and abnormal neutrophil kinetics akin
to those shown in naturally occurring acute asthma.
There are several explanations for these negative
results. Firstly, the time course of the measure-
ments made after PAF challenge may be too short
to increase systemic markers of oxidative stress.
Secondly, the inflammatory response after PAF
exposure may be less than that produced in
spontaneous acute asthma where systemic oxida-
tive stress occurred. Thirdly, PAF exposure may
simply induce an inflammatory response but not
oxidative stress. Interestingly, the administration
of PAF was associated with an increase in uLTE4
elimination, thereby reflecting an integrated form
of endogenous whole body cysteinyl LTC4 and LTD4
release during the study. Leukotrienes may be
involved as secondary mediators in the production
of the systemic and pulmonary effects caused by
PAF in asthmatic patients. Thus, PAF can increase
the subsequent release of chemotactic mediator
LTB4 indicating that it may prime the constitutive
lung cells to increase the inflammatory response
relevant to the pathogenesis of asthma.6
It has been suggested that an imbalance between
oxidants and antioxidants may have a role in the
pathogenesis of acute asthma.5 However, any
potential increase in oxidant burden may be
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system to prevent the development of oxidative
stress.11 A correlation between dietary antioxidant
deficiency and asthma exacerbations has also been
proposed.12 In bronchial asthma the sources of the
increased oxidant burden include the increased
burst of reactive oxygen species (ROS) released by
circulatory or airway leukocytes or by endogenous
nitric oxide production.13–15 An oxidant–antioxi-
dant imbalance could induce pulmonary injury by
direct oxidative assault to epithelial cells16 and in
experimental acute pulmonary inflammation se-
questered pulmonary neutrophils are primed to
release ROS.17 Increases in inflammatory leuko-
cytes in the bronchoalveolar space and those
sequestered in the pulmonary microcirculation
during asthma attacks may result in an increased
oxidant burden both locally, in the lungs, and
systemically, reflected as increase in systemic
markers of oxidative stress,13,14 as has been shown
to occur in acute asthma.3 As inflammation is
associated with an increased generation of ROS,
and the biochemical environment in the asthmatic
airways is favourable for oxidant-mediated reac-
tions, it has been proposed that an oxidative stress
could be relevant to the pathogenesis of asthma.17
Inflammatory cells recruited to the asthmatic
airways have an enhanced capability to produce
ROS18 and there is also evidence of systemic
oxidative stress in asthmatics.3 Several asthma
mediators, including lipid mediators such, as
PAF,19 chemokines,20,21 adhesion molecules,22 and
eosinophil granule proteins,23 are potential stimuli
or promoters of ROS production. Fortunately, the
lungs have an extensive and potent antioxidant
defence system, present both extra- and intracel-
lularly, which protects lung cells from oxidant
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